The GenMark Diagnostics (GNMK) Receives Daily Media Impact Score of 0.31

The GenMark Diagnostics (GNMK) Receives Daily Media Impact Score of 0.31

These are some of the media headlines that may have effected AlphaOne’s scoring:

News headlines about GenMark Diagnostics (NASDAQ:GNMK) have trended positive on Monday, Alpha One reports. Alpha One, a subsidiary of Accern, ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. GenMark Diagnostics earned a news impact score of 0.31 on Alpha One’s scale. Alpha One also assigned news stories about the medical equipment provider an impact score of 50 out of 100, indicating that recent press coverage is somewhat likely to have an effect on the company’s share price in the next several days.

Shares of GenMark Diagnostics (GNMK) opened at 12.89 on Monday. GenMark Diagnostics has a 12 month low of $7.82 and a 12 month high of $13.67. The stock’s market cap is $606.95 million. The stock has a 50 day moving average of $12.99 and a 200 day moving average of $12.28. GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings data on Tuesday, May 2nd. The medical equipment provider reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. GenMark Diagnostics had a negative net margin of 98.17% and a negative return on equity of 114.35%. The firm had revenue of $12.54 million during the quarter, compared to analyst estimates of $12.55 million. On average, equities analysts anticipate that GenMark Diagnostics will post ($0.96) earnings per share for the current fiscal year.

In other GenMark Diagnostics news, insider Hany Massarany sold 8,239 shares of the stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $12.89, for a total value of $106,200.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott Mendel sold 2,135 shares of the stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $12.89, for a total transaction of $27,520.15. Following the completion of the sale, the chief financial officer now directly owns 143,079 shares of the company’s stock, valued at approximately $1,844,288.31. The disclosure for this sale can be found here. Insiders sold 15,723 shares of company stock valued at $204,328 in the last ninety days. 7.09% of the stock is owned by corporate insiders. GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:GNMK”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment